IDO1 and neoplasm: Recently, a first-in-class immune-modulatory vaccine (IO102/IO103) against IDO1 and PD-L1 targeting IDO1 and/or PD-L1-positive immunosuppressive cells and tumor cells was tested in combination with nivolumab in patients with naïve metastatic melanoma.